All patients developed neutralizing anti-bodies that could be vital in shaping the immunity against Covid-19.
Clinical tests began on March 16. All members were divided into four groups that received various doses of the vaccine. Every test subject received two various doses of the vaccine.
The vaccine is reported to have caused a strong response after two inoculations. The levels of these antibodies in patients in the group with the high doses of vaccine were four times higher than those in the patients who recovered after treatment from coronavirus. Those who received the low doses of vaccination produced anti-bodies just as much as the sick patients who recovered.
Earlier, we reported that the vaccine against Covid-19 has been successfully tested in the U.S.; the initial phase of medical tests is over. The vaccine was supposed to stimulate immune reactions in all volunteers, who received it during the first phase of the test. The primary results showed that the vaccine is effective. However, it may cause a number of side effects, such as fatigue, shivers, headache, and pain in muscles and in the place of injection.